Shares of Acadia (Nasdaq: ACAD ) are up 123% for November, for an incredible total of 363% for 2012. The company finally hit both its primary and secondary endpoints in its phase 3 trials of its first-in-class drug Pimavanserin, which treats Parkinson's disease psychosis, a condition in many as 50% of Parkinson's disease patients. The drug had previously failed to reach statistical significance because of the placebo effect in the control group, but it was able to adjust the trials to account for this and reach its goals. If these results can be repeated, then we can expect strong continued market bullishness for the company.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.